Avecor to boost research and development (R&D) into disposables for bypass operations
This article was originally published in Clinica
US company Avecor Cardiovascular plans to increase its R&D expenditure by at least 15% this year as it expands its line of disposable medical devices for heart/lung bypass and long-term respiratory support. R&D spend was $2.3 million in 1994, up 22% on the previous year.
You may also be interested in...
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.